Assessment of treatment response in tuberculosis
- PMID: 27030924
- PMCID: PMC4949330
- DOI: 10.1586/17476348.2016.1166960
Assessment of treatment response in tuberculosis
Abstract
Antibiotic treatment of tuberculosis has a duration of several months. There is significant variability of the host immune response and the pharmacokinetic-pharmacodynamic properties of Mycobacterium tuberculosis sub-populations at the site of disease. A limitation of sputum-based measures of treatment response may be sub-optimal detection and monitoring of Mycobacterium tuberculosis sub-populations. Potential biomarkers and surrogate endpoints should be benchmarked against hard clinical outcomes (failure/relapse/death) and may need tailoring to specific patient populations. Here, we assess the evidence supporting currently utilized and future potential host and pathogen-based models and biomarkers for monitoring treatment response in active and latent tuberculosis. Biomarkers for monitoring treatment response in extrapulmonary, pediatric and drug resistant tuberculosis are research priorities.
Keywords: Tuberculosis; biomarkers; humans; therapeutics; treatment outcome.
References
-
- Lobue P, Menzies D. Treatment of latent tuberculosis infection: An update. Respirology. 2010;15(4):603–622. - PubMed
-
- World Health Organization [09/01/2016];Global Tuberculosis Report 2015. 2015 http://www.who.int/tb/publications/global_report/gtbr2015_executive_summ....
-
- World Health Organization [09/01/2016];Definitions and reporting framework for tuberculosis–2013 revision. http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?....
-
- Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 2006;174(8):935–952. - PubMed